- Lipitor may be the first statin to switch to OTC
- ROUNDTABLE: Pharmacy’s future in sync with technology
- FDA approves Bristol-Myers Squibb's, AstraZeneca's Farxiga
- Suppliers counteract generic margin compression with targeted mergers, acquisitions
- Roxane Labs' generic prostate drug gets tentative approval from FDA
PARSIPPANY, N.J. — Generic drug maker Actavis has reached a deal with AstraZeneca that will allow it to launch a version of a drug used to treat cholesterol in three years, Actavis said Monday.
Under a deal to settle a patent-infringement lawsuit, Actavis will be allowed to launch its generic version of Crestor (rosuvastatin calcium) tablets in the 5-mg, 10-mg, 20-mg and 40-mg strengths 67 days before July 8, 2016, when the drug's market exclusivity for use in children expires, at a fee of 39% of net sales to AstraZeneca.
Actavis also can launch rosuvastatin zinc alternate salt starting on May 2, 2016, but the company said it had made no decision regarding a potential launch.
"This agreement ensures that consumers will benefit from an earlier launch of a rosuvastatin calcium product and eliminates ongoing litigation and uncertainty of marketplace acceptance of a non-generically substitutable product if Actavis had proceeded to launch the alternative product," Actavis president and CEO Paul Bisaro said.
Crestor had sales of $4.4 billion in 2011, according to IMS Health.